TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus

Cristiana Guiducci, Mei Gong, Zhaohui Xu, Michelle Gill, Damien J. Chaussabel, Thea Meeker, Jean H. Chan, Tracey Wright, Marilynn Punaro, Silvia Bolland, Vassili Soumelis, Jacques Banchereau, Robert L. Coffman, Virginia Pascual, Franck J. Barrat

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

Glucocorticoids are widely used to treat patients with autoimmune diseases such as systemic lupus erythematosus (SLE). However, regimens used to treat many such conditions cannot maintain disease control in the majority of SLE patients and more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide transient reductions in disease activity. The primary anti-inflammatory mechanism of glucocorticoids is thought to be NF-B inhibition. Recognition of self nucleic acids by toll-like receptors TLR7 and TLR9 on B cells and plasmacytoid dendritic cells (PDCs) is an important step in the pathogenesis of SLE, promoting anti-nuclear antibodies and the production of type I interferon (IFN), both correlated with the severity of disease. Following their activation by self-nucleic acid-associated immune complexes, PDCs migrate to the tissues. We demonstrate, in vitro and in vivo, that stimulation of PDCs through TLR7 and 9 can account for the reduced activity of glucocorticoids to inhibit the IFN pathway in SLE patients and in two lupus-prone mouse strains. The triggering of PDCs through TLR7 and 9 by nucleic acid-containing immune complexes or by synthetic ligands activates the NF-B pathway essential for PDC survival. Glucocorticoids do not affect NF-B activation in PDCs, preventing glucocorticoid induction of PDC death and the consequent reduction of systemic IFN-α levels. These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs.

Original languageEnglish
Pages (from-to)937-941
Number of pages5
JournalNature
Volume465
Issue number7300
DOIs
Publication statusPublished - 17 Jun 2010
Externally publishedYes

Fingerprint

Dendritic Cells
Nucleic Acids
Glucocorticoids
Systemic Lupus Erythematosus
Antigen-Antibody Complex
Interferons
Interferon Type I
Toll-Like Receptors
Methylprednisolone
Autoimmune Diseases
Antibody Formation
Anti-Idiotypic Antibodies
Cell Survival
Adrenal Cortex Hormones
B-Lymphocytes
Cell Death
Anti-Inflammatory Agents
Ligands
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Guiducci, C., Gong, M., Xu, Z., Gill, M., Chaussabel, D. J., Meeker, T., ... Barrat, F. J. (2010). TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature, 465(7300), 937-941. https://doi.org/10.1038/nature09102

TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. / Guiducci, Cristiana; Gong, Mei; Xu, Zhaohui; Gill, Michelle; Chaussabel, Damien J.; Meeker, Thea; Chan, Jean H.; Wright, Tracey; Punaro, Marilynn; Bolland, Silvia; Soumelis, Vassili; Banchereau, Jacques; Coffman, Robert L.; Pascual, Virginia; Barrat, Franck J.

In: Nature, Vol. 465, No. 7300, 17.06.2010, p. 937-941.

Research output: Contribution to journalArticle

Guiducci, C, Gong, M, Xu, Z, Gill, M, Chaussabel, DJ, Meeker, T, Chan, JH, Wright, T, Punaro, M, Bolland, S, Soumelis, V, Banchereau, J, Coffman, RL, Pascual, V & Barrat, FJ 2010, 'TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus', Nature, vol. 465, no. 7300, pp. 937-941. https://doi.org/10.1038/nature09102
Guiducci, Cristiana ; Gong, Mei ; Xu, Zhaohui ; Gill, Michelle ; Chaussabel, Damien J. ; Meeker, Thea ; Chan, Jean H. ; Wright, Tracey ; Punaro, Marilynn ; Bolland, Silvia ; Soumelis, Vassili ; Banchereau, Jacques ; Coffman, Robert L. ; Pascual, Virginia ; Barrat, Franck J. / TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. In: Nature. 2010 ; Vol. 465, No. 7300. pp. 937-941.
@article{672225655c4e4a07a9e279371e1fa972,
title = "TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus",
abstract = "Glucocorticoids are widely used to treat patients with autoimmune diseases such as systemic lupus erythematosus (SLE). However, regimens used to treat many such conditions cannot maintain disease control in the majority of SLE patients and more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide transient reductions in disease activity. The primary anti-inflammatory mechanism of glucocorticoids is thought to be NF-B inhibition. Recognition of self nucleic acids by toll-like receptors TLR7 and TLR9 on B cells and plasmacytoid dendritic cells (PDCs) is an important step in the pathogenesis of SLE, promoting anti-nuclear antibodies and the production of type I interferon (IFN), both correlated with the severity of disease. Following their activation by self-nucleic acid-associated immune complexes, PDCs migrate to the tissues. We demonstrate, in vitro and in vivo, that stimulation of PDCs through TLR7 and 9 can account for the reduced activity of glucocorticoids to inhibit the IFN pathway in SLE patients and in two lupus-prone mouse strains. The triggering of PDCs through TLR7 and 9 by nucleic acid-containing immune complexes or by synthetic ligands activates the NF-B pathway essential for PDC survival. Glucocorticoids do not affect NF-B activation in PDCs, preventing glucocorticoid induction of PDC death and the consequent reduction of systemic IFN-α levels. These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs.",
author = "Cristiana Guiducci and Mei Gong and Zhaohui Xu and Michelle Gill and Chaussabel, {Damien J.} and Thea Meeker and Chan, {Jean H.} and Tracey Wright and Marilynn Punaro and Silvia Bolland and Vassili Soumelis and Jacques Banchereau and Coffman, {Robert L.} and Virginia Pascual and Barrat, {Franck J.}",
year = "2010",
month = "6",
day = "17",
doi = "10.1038/nature09102",
language = "English",
volume = "465",
pages = "937--941",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7300",

}

TY - JOUR

T1 - TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus

AU - Guiducci, Cristiana

AU - Gong, Mei

AU - Xu, Zhaohui

AU - Gill, Michelle

AU - Chaussabel, Damien J.

AU - Meeker, Thea

AU - Chan, Jean H.

AU - Wright, Tracey

AU - Punaro, Marilynn

AU - Bolland, Silvia

AU - Soumelis, Vassili

AU - Banchereau, Jacques

AU - Coffman, Robert L.

AU - Pascual, Virginia

AU - Barrat, Franck J.

PY - 2010/6/17

Y1 - 2010/6/17

N2 - Glucocorticoids are widely used to treat patients with autoimmune diseases such as systemic lupus erythematosus (SLE). However, regimens used to treat many such conditions cannot maintain disease control in the majority of SLE patients and more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide transient reductions in disease activity. The primary anti-inflammatory mechanism of glucocorticoids is thought to be NF-B inhibition. Recognition of self nucleic acids by toll-like receptors TLR7 and TLR9 on B cells and plasmacytoid dendritic cells (PDCs) is an important step in the pathogenesis of SLE, promoting anti-nuclear antibodies and the production of type I interferon (IFN), both correlated with the severity of disease. Following their activation by self-nucleic acid-associated immune complexes, PDCs migrate to the tissues. We demonstrate, in vitro and in vivo, that stimulation of PDCs through TLR7 and 9 can account for the reduced activity of glucocorticoids to inhibit the IFN pathway in SLE patients and in two lupus-prone mouse strains. The triggering of PDCs through TLR7 and 9 by nucleic acid-containing immune complexes or by synthetic ligands activates the NF-B pathway essential for PDC survival. Glucocorticoids do not affect NF-B activation in PDCs, preventing glucocorticoid induction of PDC death and the consequent reduction of systemic IFN-α levels. These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs.

AB - Glucocorticoids are widely used to treat patients with autoimmune diseases such as systemic lupus erythematosus (SLE). However, regimens used to treat many such conditions cannot maintain disease control in the majority of SLE patients and more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide transient reductions in disease activity. The primary anti-inflammatory mechanism of glucocorticoids is thought to be NF-B inhibition. Recognition of self nucleic acids by toll-like receptors TLR7 and TLR9 on B cells and plasmacytoid dendritic cells (PDCs) is an important step in the pathogenesis of SLE, promoting anti-nuclear antibodies and the production of type I interferon (IFN), both correlated with the severity of disease. Following their activation by self-nucleic acid-associated immune complexes, PDCs migrate to the tissues. We demonstrate, in vitro and in vivo, that stimulation of PDCs through TLR7 and 9 can account for the reduced activity of glucocorticoids to inhibit the IFN pathway in SLE patients and in two lupus-prone mouse strains. The triggering of PDCs through TLR7 and 9 by nucleic acid-containing immune complexes or by synthetic ligands activates the NF-B pathway essential for PDC survival. Glucocorticoids do not affect NF-B activation in PDCs, preventing glucocorticoid induction of PDC death and the consequent reduction of systemic IFN-α levels. These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs.

UR - http://www.scopus.com/inward/record.url?scp=77953723966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953723966&partnerID=8YFLogxK

U2 - 10.1038/nature09102

DO - 10.1038/nature09102

M3 - Article

VL - 465

SP - 937

EP - 941

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7300

ER -